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SUMMARY
Background
Although irritable bowel syndrome (IBS) is a multisymptom disorder,
abdominal pain drives illness severity more than other symptoms. Despite
consensus that IBS trials should measure pain to define study entry and
determine efficacy, the optimal method of measuring pain remains uncer-
tain.
Aim
To determine whether combining information from multiple pain dimen-
sions may capture the IBS illness experience more effectively than the
approach of measuring ‘pain predominance’ or pain intensity alone.
Methods
Irritable bowel syndrome patients rated dimensions of pain, including
intensity, frequency, constancy, predominance, predictability, duration,
speed of onset and relationship to bowel movements. We evaluated the
impact of each dimension on illness severity using multivariable regression
techniques.
Results
Among the pain dimensions, intensity, frequency, constancy and predict-
ability were strongly and independently associated with illness severity; the
other dimensions had weaker associations. The clinical definition of ‘pain
predominance’, in which patients define pain as their most bothersome
symptom, was insufficient to categorize patients by illness severity.
Conclusions
Irritable bowel disease pain is multifaceted; some pain dimensions drive ill-
ness more than others. IBS trials should measure various pain dimensions,
including intensity, constancy, frequency and predictability; this may
improve upon the customary use of measuring pain as a unidimensional
symptom in IBS.
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INTRODUCTION
Although irritable bowel syndrome (IBS) is a multisymp-
tom disorder, abdominal pain is a defining characteristic1
and a driver of healthcare resource utilization.2–4 Unlike
most other IBS symptoms, such as bloating or abnormal-
ities in stool frequency or form, abdominal pain inde-
pendently drives health-related quality of life (HRQOL)
decrements in IBS5 and is the principal driver of patient-
reported symptom severity.4, 6, 7 In short, IBS is partly
defined by pain, and pain is the cornerstone of the IBS
illness experience for many patients.
However, as with other types of chronic pain, the pain
of IBS is complex and multifaceted. As some dimensions
of IBS pain may drive illness severity more than others,
it is simplistic to treat pain as a unidimensional symp-
tom. Data indicate that pain intensity, as measured by a
numeric rating scale (NRS), is highly predictive of
HRQOL and other severity measures in IBS,7 but less is
known about the incremental value of other IBS pain
dimensions, including frequency, constancy, duration,
bothersomeness, predictability, speed of onset and rela-
tionship to bowel movements. In other chronic pain con-
ditions, pain is typically assessed in terms of its affective
impact, sensory intensity and pain descriptors (e.g.
cramping, throbbing and aching).8, 9 It is important to
understand the predictive value of different pain dimen-
sions in IBS, not only to guide patient-reported outcome
(PRO) measurement for future clinical trials but also to
define better the inclusion criteria for these trials in the
first place. Similarly, it is important to define clearly
‘pain predominance’ in IBS, as future clinical trials of
visceral analgesics may aim to recruit patients who
describe pain as their predominant symptom. As pain
has many dimensions, it remains unclear which dimen-
sions of pain should be employed to define ‘pain pre-
dominance’ in IBS.
In this study, we performed analyses using a well-
defined IBS cohort to measure the impact of individual
pain dimensions on illness severity. We hypothesized
that different pain dimensions have varying abilities to
predict illness severity. We further hypothesized that
combining information from multiple dimensions may
capture the IBS illness experience more effectively than
measuring individual dimensions alone. Finally, we
hypothesized that the clinical definition of ‘pain predom-
inance’, in which patients define pain as their most both-
ersome symptom,10 may be necessary, but is insufficient
to categorize optimally patients by illness severity; it may
be more useful to define pain predominance by combin-
ing multiple symptom dimensions.
METHODS
Patients
We prospectively evaluated patients aged 18 years or older
with Rome III positive IBS (including IBS-C, IBS-D and
IBS-M) enrolled in the IBS Patient Reported Observed
Outcomes and Function (PROOF) cohort. The current
study presents data obtained from a new survey of this
cohort. An overview of the PROOF methodology can be
found in previous publications.7, 11 PROOF is an internet-
based, longitudinal, observational registry of IBS patients
from a network of eight geographically diverse U.S.
centres. PROOF does not mandate specified treatments or
protocols; patients receive the usual care of their healthcare
providers. Each PROOF investigator is an experienced gas-
troenterologist with knowledge of the appropriate applica-
tion of the Rome III criteria. The study was approved by
the University of California at Los Angeles Institutional
Review Board and was conducted in accordance with the
institutional guidelines regulating human subject research.
IBS pain dimensions
Pain can be measured with several dimensions. In this
study, we identified and prospectively measured two sets
of IBS pain dimensions: one set pertaining to the overall
pain experience of IBS, and one set related specifically to
IBS acute pain episodes, defined as discrete periods when
IBS pain starts or worsens. Acute pain episodes are vari-
ably described as ‘flare-ups’,5 ‘attacks’12 and ‘break-
through’ pain episodes, and are experienced by many
patients with IBS symptoms.
Dimensions of overall pain experience. We measured the
following dimensions of the overall IBS pain experience:
• Intensity: Data from the chronic pain literature
indicate that pain intensity is a key attribute to monitor
for both study entry and outcome measurement.13 We
therefore measured IBS pain intensity with a 10-point
abdominal pain NRS with the following question: ‘On a
scale from 1 (no pain) to 10 (worst possible pain), how
bad has your abdominal pain been, on average, over the
last 10 days?’ This is a modification of the 11-point NRS
supported by the Initiative on Methods, Measurement,
and Pain Assessment in Clinical Trials (IMMPACT) for
the non-IBS pain literature.13, 14 We have found that the
10-point NRS behaves in a nearly identical psychometric
manner as the 11-point NRS.7
• Frequency: In addition to pain intensity, it is impor-
tant to understand the frequency by which pain occurs,
independent of intensity. We asked patients to rate the
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frequency of their abdominal pain over a typical 10-day
period using an item derived from the IBS Symptom
Severity Scale (IBS-SSS) instrument.15 Patients were
instructed to ‘enter the number of days that you get pain
in every 10 days. For example, if you enter 4, it means
that you get pain four out of every 10 days. If you get
pain every day, enter 10’.
• Constancy: Clinicians recognize that some patients
with IBS always have pain, whereas others describe cycles
of pain periodicity. We posed the following question
derived from the Functional Bowel Disease Severity
Index (FBDSI) Instrument:16 ‘Is your abdominal pain
constant? (i.e. present all of the time and everyday?)’.
• Relationship with bowel movements: Many patients
with IBS obtain relief of their pain upon stool passage.
Although pain relief with defecation is part of the Rome
III diagnostic criteria for IBS, its presence is not manda-
tory to diagnose the syndrome.1 As defecation is partly
under voluntary control, it is possible that patients with
pain relieved by defecation maintain better control over
their abdominal pain and, perhaps, are better able to cope
with their illness. However, this hypothesis has not been
formally tested. We asked patients to rate the frequency
that abdominal pain improves or stops after a bowel
movement using a five-point Likert scale from the Rome
III battery,1 as follows: 1 – ‘never or rarely’; 2 – ‘some-
times’; 3 – ‘often’; ‘4 – ‘most of the time’; 5 – ‘always’.
• Pain predominance: The Rome III IBS guidelines
suggest that clinicians should identify and focus treat-
ment efforts on the patients’ primary or ‘most bother-
some’ symptom.1 Although IBS is a multisymptom
disorder, it is often helpful to understand which symp-
tom is predominant in each patient’s illness experience,
and to ensure that the treatment plan addresses that
symptom. However, it remains unclear whether this clin-
ical definition of pain predominance is a reliable predic-
tor of global illness severity. We therefore posed the
following question, which has been previously used as a
measure of symptom ‘predominance’10: ‘If you could get
rid of the single most bothersome IBS symptom, which
one would you choose?’ Patients could select one from a
list of nine cardinal IBS symptoms, including ‘belly pain’.
We stratified patients into those who endorsed pain as
their most bothersome symptom vs. those who did not –
a previously employed measure of pain predominance.10
Dimensions of IBS acute pain episodes. In addition to
measuring dimensions of the overall pain experience, we
measured several dimensions of IBS acute pain episodes.
Recent literature has focused on pain episodes as a
potentially important part of the overall pain experience
in IBS. These pain episodes have been the target of at
least one clinical drug trial,12 and have also been recently
described and characterized in various cohorts of IBS
patients outside the context of clinical trials.17–19 We first
asked patients whether they experience acute painful epi-
sodes (as opposed to ‘discomfort’ alone), and limited our
subsequent analyses only to those patients who reported
acute pain episodes. As different patients use different
words to describe a pain episode, we next asked patients
to select among a group of descriptors for their acute
pain episodes, including ‘pain attack’, ‘pain break-
through’, ‘pain flare-up’, ‘pain bout’ and ‘pain episode’
itself. The descriptors were displayed in random order to
minimize the risk of order effect. In addition, patients
could provide their own descriptors using an open-ended
field. The online survey automatically incorporated the
patients’ own language into the questions that followed
(e.g. if a patient described his ⁄ her pain episodes as
‘attacks’, then the survey referred to ‘attacks’ to ensure
that the language was concordant with the patients’ per-
sonal semantics). For simplicity, we will refer to these
periods as ‘pain episodes’ throughout the manuscript.
Patients endorsing the presence of acute pain episodes
were asked to rate the following dimensions of their
episodes:
• Intensity: We asked patients: ‘During a typical IBS
pain episode, how severe does your pain get on a scale
from 0 (no pain) to 10 (worst imaginable pain)?’ Patient
responded using the 11-point NRS supported by IMM-
PACT14 and the FDA.20
• Frequency: We asked patients to estimate the fre-
quency of their acute pain episodes over a defined 30-
day period. We selected this time period based on recall
periods for previous clinical trial work measuring acute
pain episodes in IBS.12 Patients were instructed to ‘indi-
cate about how many days you have pain episodes over
a typical 30-day period. For example, if you select four,
it means that you have pain episodes four out of every
30 days. If you have episodes every day, select 30’. In
addition, we sought to measure the average number of
episodes experienced per day. Patients were asked: ‘On a
typical day when you do have an IBS pain episode, how
many episodes do you have during the day? For exam-
ple, if you select 4, that means you experience 4 pain
episodes during a typical day (even if your pain episodes
varies from day to day, please give us your best
estimate)’.
• Duration: The duration of acute pain episodes may
impact illness severity independent of frequency and
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intensity. We asked patients: ‘When you do have a pain
episode, about how long does your episode typically last?’
Patient selected among the following options: ‘less than
10 min’, ‘10–30 min’, ‘30 min to 1 h’, ‘1–4 h, ‘all day
long’, ‘2 days long’ and ‘more than 2 days long’.
• Speed of onset: Some patients describe pain episodes
that come on rapidly over seconds or minutes. Others
describe pain that builds and crescendos over a longer
period. As it is possible that speed of onset may be an
independent dimension of pain episodes, we asked
patients: ‘When you have an IBS pain episode, about
how quickly does the episode usually come on?’. Patients
selected among the following options: ‘seconds to a min-
ute’, ‘1–5 min’, ‘5–10 min’, ‘10–30 min’, ‘30 min to an
hour’, ‘over 1–2 h’ and ‘several hours’.
• Predictability: The predictability of pain has impor-
tant clinical implications. In migraine headache, patients
who can detect a preceding aura may reach for timely
therapeutic interventions in anticipation of the inevitable
headache to follow, whereas those without an aura may
be less likely to initiate timely therapy. The same may
apply to IBS; some patients describe situational, physical
or psychosocial cues that reliably predict an oncoming
pain episode, whereas others lack this predictive ability
and suffer pain episodes without detectable warning. We
posed the following question: ‘Some people with IBS can
predict when a pain episode is about to come on while
others cannot. In thinking about your IBS pain episodes,
how reliably can you predict, in advance, that an episode
is about to happen on a scale from 0 (IBS episodes are
totally unpredictable) to 10 (IBS episodes are totally pre-
dictable)?’
Analyses
Predictive value of ‘pain predominance’. We first evalu-
ated the clinical definition of pain predominance, mea-
sured using the definition described above and suggested
by previous authors10 and the Rome III guidance.1 We
performed a series of bivariate analyses to compare the
pain-predominant vs. nonpain-predominant patients
across a range of metrics. Specifically, we measured IBS
symptom severity with the Irritable Bowel Severity Scor-
ing System,15 FBDSI16 and BEST score,21 disease-targeted
HRQOL with the IBS-QOL instrument,22 generic
HRQOL with the EQ5D11, 23 and CDC-4, worker pro-
ductivity with the IBS version of the Work Productivity
Activity Index (WPAI:IBS),24 gastrointestinal-specific
anxiety with the visceral sensitivity index (VSI),25, 26 gen-
eric psychological function with the Hospital Anxiety
and Depression (HAD) scale and symptom coping using
a five-point Likert scale. Finally, we measured resource
utilization, including self-reported physician visits and
current number of IBS therapies. We used t-tests to
compare continuous variables between groups and chi-
squared tests for categorical variables. We expressed the
bivariate relationship between pain predominance and
each index using a T-value, P-value and Pearson’s corre-
lation coefficient, and employed a P-value of <0.05 as
evidence for statistical significance. As we evaluated mul-
tiple comparisons, we calculated a Bonferroni-corrected
P-value for each bivariate analysis.
Incremental value of individual pain dimensions. We
next conducted a series of multivariable regression analy-
ses to measure the independent contribution of each
pain dimension stratified by IBS illness severity metrics.
We first conducted models to measure the five dimen-
sions of the overall pain experience, and then conducted
a second set of models to evaluate the five dimensions of
acute pain episodes. We calculated the proportion of var-
iance for each illness severity metric explained by the
models, expressed with the R2-statistic, and measured the
P-value for each attribute’s beta coefficient. In addition,
we calculated the squared semi-partial correlations of
each pain attribute to measure the unique proportion of
variance in each illness severity metric accounted for by
each pain dimension after removing the effects of shared
variance. We depict the semi-partial correlations with
tiered bar grafts demonstrating the relative influence of
competing pain dimensions, along with the absolute R2
explained by each model.
RESULTS
Patient characteristics
Table 1 provides characteristics of the 258 patients in the
analyses. The patient profiles are consistent with previous
studies in IBS. Namely, the patients were primarily middle
aged (mean age = 43  15 years) and women (82%). The
population was varied across demographic characteristics,
including race, education and income. Eighteen per cent
of the cohort had IBS-C, 29% IBS-D and 53% IBS-M
using Rome III subclassification criteria.1 Using IBS-SSS
criteria for symptom severity, 17%, 46% and 37% of
patients had mild, moderate and severe IBS symptoms.
Predictive value of ‘pain predominance’
Eighty four per cent of the patients in PROOF reported
experiencing abdominal pain within the previous 10 days
of the survey. Of this group, 19% had ‘pain predominant
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IBS’, defined as pain being the most bothersome symp-
tom.10 Table 2 provides the bivariate relationships
between patients with vs. without pain predominance.
There were no significant differences between groups for
all but five of the 17 metrics – that is, the clinical defini-
tion of pain predominance (pain as ‘most bothersome’
symptom) was not generally predictive of illness severity.
There were no significant differences between groups
when applying a Bonferroni correction requiring a
P £ 0.003.
Incremental value of individual pain dimensions
Dimensions of overall pain experience. Table 3 displays
the results of regression analyses stratified by IBS severity
metrics. The P-values in Table 3 present the significance
level beta-coefficients for individual pain dimensions
derived from regression models, and therefore measure
significance while adjusting for simultaneously measured
pain dimensions. Figure 1 depicts the relative contribu-
tion of each pain dimension towards explaining the vari-
ance in each index. Among the various pain dimensions,
the ‘predominance’ and ‘relation to bowel movement’
dimensions were least predictive across metrics, whereas
intensity, frequency and constancy were most predictive.
When analysed as a group, the pain dimensions
explained the largest proportion of variance for overall
symptom severity (R2 = 80% for IBS-SSS; R2 = 29% for
severity NRS), IBS-QOL scores (R2 = 25%) and presen-
teeism (R2 = 21%). The pain dimensions explained the
lowest proportion of variance for generalized anxiety
(6%) as measured by HAD.
Dimensions of IBS acute pain episodes. We analysed
data from 146 patients who reported experiencing epi-
sodes of acute pain. These patients most frequently
referred to the episodes as ‘pain flare-ups’ (34%), followed
by ‘pain episodes’ (28%), ‘pain attacks’ (19%), ‘pain bouts’
(6%) and ‘pain breakthroughs’ (1%). Thirteen per cent of
respondents selected an alternative to the available cate-
gories, such as ‘cramp attack’, ‘stomach bother’ and ‘IBS
cycle’, among others. Table 4 and Figure 2 displays the
results of regression analyses using the pain episode
dimensions as predictors of illness severity. Among the
acute pain dimensions, predictability (i.e. ability to pre-
dict an episode is coming) was most strongly associated
with the IBS illness severity metrics. Figure 3 presents the
distribution of patient ability to predict acute pain
attacks. In contrast, the intensity of acute episodes was
not predictive across metrics (unlike the predictive ability




Age (mean years  s.d.) 42  15










<$50 000 annual 49
$50 000 to $100 000 annual 29
>$100 000 annual 22
Marital status (% married) 48
IBS subtype (%)
IBS with constipation (IBS-C) 18
IBS with diarrhoea (IBS-D) 29
Mixed IBS (IBS-M) 53
IBS duration (%)





More than 20 years 16.1
IBS pain severity (10-point numeric rating scale)
In all patients at baseline 4.5  2.5
In patients with ‡3 out of 10 points at
baseline
5.6  2.0
Global IBS severity (0–20 rating scale) 11  5
IBS-SSS trichotomized severity (%)
Mild (score of 75–175) 17
Moderate (score of 175–300) 46
Severe (>300) 37
IBS-QOL overall score (mean  s.d.) 62.7  22
Worker Productivity Activity Index (WPAI:IBS) (%)
Work week absent from IBS
(absenteeism)
3.6
Work week impaired from IBS
(presenteeism)
34.4
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of overall pain intensity; Table 3). Similarly, the fre-
quency of acute pain episodes had minimal predictive
value. When analysed as a group, the pain episode
dimensions explained the largest proportion of variance
(R2) for IBS-SSS (78%), weekly symptom severity ratings
(36%) and assessment of ‘adequate relief’ (26%). As with
the pain dimensions for the overall pain experience, the
pain attack dimensions also explained the lowest propor-
tion of variance for generalized anxiety (5%).
DISCUSSION
Whereas the Rome III criteria for IBS allow either
abdominal pain or discomfort,1 earlier diagnostic criteria,
such as the Kruis et al.,27 Manning et al.28 and Rome I,29
specified pain as the hallmark symptom of IBS. Although
IBS is a multisymptom disorder, most patients report at
least some abdominal pain attributable to their IBS.
Moreover, abdominal pain is the principal driver of ill-
ness severity in IBS, and drives HRQOL more than any
other bowel symptom.4–6 In short, IBS can be reasonably
classified as a persistent pain syndrome in many patients;
PRO measures for IBS clinical trials must capture the
pain experience in a reliable and valid manner.
In this study, we explored the various dimensions of
pain in IBS to help guide PRO measurement for future
clinical trials, and also to define better the inclusion
criteria for trials that seek to measure and treat abdomi-
nal pain in IBS. This approach is consistent with PRO
guidance in other chronic pain disorders that emphasize
the multidimensionality of pain. For example, the NIH-
sponsored Patient Reported Outcomes Measurement
Information System (PROMIS) includes a pain instru-
ment that specifies intensity, duration and frequency of
pain.30 Although the multidimensionality of pain is well
accepted in PROMIS, there has been relatively little work
performed to explore this concept in IBS.
Our study has four key findings: first, although we
confirmed previous data that measuring pain intensity is
important in IBS,4, 6 we found that this is necessary, but
not sufficient to understand fully the global pain experi-
ence in IBS. Instead, future IBS pain measures should
also evaluate the frequency and constancy of pain, as
these dimensions each provide incremental explanatory
value over and above pain intensity alone. In addition,
measuring the predictability of pain may be important
for understanding the acute pain experience in IBS.




mean (n = 190)
Pain
predominant
mean (n = 45) T-value r-Value P-value
General health (1–4; lower = worse) 2.35 2.42 )0.42 )0.164 0.68
Symptom coping (1–5; lower = worse) 4.12 3.91 1.06 )0.608 0.29
HAD Anxiety Scale Score (0–30; higher = worse) 3.31 3.42 )0.35 0.269 0.72
HAD Depression Scale Score (0–30; higher = worse) 2.19 2.22 )0.13 0.425 0.90
VSI Scale Score (0–75; higher = worse) 39.80 48.27 )2.91 0.456 0.004
Severity of symptoms past week (0–20; higher = worse) 10.31 10.58 )0.34 0.575 0.73
CDC4 Score (0–30; higher = worse) 25.27 24.20 0.29 0.197 0.77
IBS QOL Score (0–100; lower = worse) 63.29 60.58 0.73 -0.523 0.47
FBDSI Scale Score 80.89 102.73 )2.05 0.307 0.04
EuroQual Utility Score (0–1; lower = worse) 0.69 0.64 1.19 -0.393 0.24
BEST Scale Score (0–100; higher = worse) 37.93 39.80 )0.79 0.352 0.43
IBS-SSS Scale Score (0–500; higher = worse) 267.17 304.09 )2.28 0.644 0.02
WPAI absenteeism (% week absent from IBS) 3.06 5.86 )1.15 0.391 0.25
WPAI presenteeism (% week impaired at work from IBS) 32.11 44.41 )2.58 0.609 0.01
No. IBS therapies currently receiving (out of 16) 1.48 1.33 0.57 0.100 0.57
No. physician visits in previous year 2.49 4.20 )2.64 0.124 0.009
Patients with pain predominant IBS state that pain is their ‘most bothersome’ symptom. The data reveal only minimal differences
in illness severity between groups using this definition. When using a Bonferroni correction for multiple testing (requiring a signif-
icance threshold of P £ 0.003), none of the relationships was significant.
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These findings should be borne in mind as investigators
develop and refine conceptual frameworks for future
PROs in IBS. Additional research in other IBS cohorts
should further explore the dimensionality of pain in IBS
to evaluate whether similar findings emerge.
Second, we found that the clinical definition of pain
predominance, in which patients describe pain as their
most bothersome symptom,1, 10 is inadequate to gauge
fully the overall illness severity in IBS; however, measur-
ing pain predominance does correlate with total physi-
cian visits, visceral anxiety and work productivity
(Table 2). The suboptimal performance of pain predomi-
nance is similar to previous data that patients reporting
pain as their most bothersome symptom have a similar
psychological and symptom burden as those who do
not.10 This has clinical implications as physicians often
ask patients to identify their most bothersome symptom
to determine the course of questioning and subsequent
treatment. Our data suggest that although measuring
pain predominance may provide some sense of overall
distress, it is not sufficient to understand the overall pain
experience of IBS. That is, fully understanding IBS pain
will require sampling multiple dimensions of pain – not
merely whether it is the most bothersome symptom.
Third, from the viewpoint of a clinical trial design,
our data suggest that trials aimed at treating the pain of
IBS should not employ inclusion criteria on the basis of
a single pain dimension (e.g. only enrolling patients with
a pain NRS score of ‡320, 31). Instead, trials may be bet-
ter served to consider multiple dimensions of pain when
determining study eligibility. Future research should
develop and validate multidimensional criteria to deter-
mining study eligibility; measuring one pain dimension
alone may be inadequate to craft a study population.
Fourth, we found that among patients who experi-
ence acute pain episodes, the predictability of the epi-
sodes is the most important determinant of overall
illness severity. This is consistent with the finding that
anticipatory concerns are common in patients with IBS,
particularly when symptoms wax and wane with limited
predictability. A recent study found that few IBS
patients know where, when, or what triggers a symptom





equationIntercept Predominance Severity Constancy Frequency
Relief
with BM
General health 0.0000 0.52 0.74 0.41 0.01 0.38 0.07
Symptom coping 0.0000 0.38 0.0005 0.0002 0.90 0.09 0.17
HAD Anxiety Scale Score 0.0000 0.93 0.44 0.75 0.39 0.67 0.02
HAD Depression Scale Score 0.0003 0.42 0.04 0.006 0.22 0.71 0.12
VSI Scale Score 0.0000 0.11 0.16 0.001 0.07 0.70 0.16
Severity of symptoms past week 0.0000 0.03 0.0001 0.006 0.0008 0.97 0.29
Considerable relief? 0.0000 0.62 0.12 0.32 0.007 0.25 0.20
CDC4 Score 0.0000 0.12 0.58 0.001 0.01 0.04 0.16
IBS-QOL Score 0.0000 0.15 0.001 0.0002 0.02 0.71 0.24
FBDSI severity 0.0000 0.92 0.05 0.26 0.11 0.02 0.13
EuroQual Utility Score 0.0000 0.44 0.0006 0.001 0.02 0.47 0.24
BEST Scale Score 0.0000 0.45 0.007 0.16 0.05 0.32 0.14
Absenteeism 0.2503 0.96 0.16 0.02 0.38 0.26 0.07
Presenteeism 0.0003 0.74 0.0003 0.67 0.48 0.26 0.21
No. therapies 0.0000 0.23 0.12 0.71 0.59 0.005 0.07
No. physician visits 0.0090 0.15 0.13 0.77 0.64 0.23 0.05
Each cell provides the P-value for the beta-coefficient of each pain attribute in the model. Bold values indicate statistical signifi-
cance. The data reveal that pain ‘predominance’ and ‘relief with bowel movements (BM)’ were not predictive of most indices. In
contrast, pain ‘severity’, ‘frequency’ and ‘constancy’ were highly predictive of most indices. Taken together, the pain dimensions
explained the largest proportion of variance (R2) for weekly symptom severity ratings (29%) and IBS-QOL (24%).
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flare.32 Patients often engage in advanced planning to
pursue normal activities, such as knowing the locations
of bathrooms out of the home, planning out meals, and
reducing participation in daily activities. Anticipatory
anxiety of pain, in particular, plays an important role in
central pain amplification in chronic pain states. Com-
pared with healthy controls, IBS patients demonstrate a
greater startle response after receiving an aversive
abdominal stimulation.33 This suggests that anticipatory
fear of pain may amplify the intensity of pain and
therefore contribute to overall illness severity. These
observations are not limited to IBS; other digestive dis-
orders, notably inflammatory bowel disease, lead to
anticipatory concerns of impending disease flares.34 In
this study, we found a wide variation in patients’ ability
to predict acute pain episodes in IBS (Figure 3), with
the most prevalent response that pain episodes are
‘totally unpredictable’; <3% of patients reported episodes
that were ‘totally predictable’. Moreover, we found that
patients who are better at predicting pain in advance of
an acute episode have higher overall HRQOL, lower
symptom severity, improved work productivity, less
depression and better symptom control compared with
those who cannot reliably predict when an episode will
occur. Future research should further explore this con-
cept of pain predictability and also determine whether
and how to incorporate predictability into both PROs
and everyday clinical care.
Our findings regarding pain predictability have poten-
tial clinical and academic implications. Clinically, provid-
ers should routinely ask patients to assess their ability to
predict painful attacks. Patients who cannot reliably pre-
dict pain onset might benefit from maintaining a journal
to identify contextual cues that are associated with their
painful episodes, such as dietary, social, psychological,
temporal or other predictive factors. This might
empower patients to help manage their disease and mini-
mize the cycle of anticipatory anxiety. For clinical trials
aimed at treating painful episodes in IBS, both inclusion
criteria and outcomes measurement might benefit from
capturing information about pain predictability. Finally,
this finding suggests that rapid acting visceral analgesics
may play an important role in IBS for patients able to
predict the onset of an acute pain episode with sufficient
time to spare – similar to the paradigm for acute







































































































equation (%) 9 20 25 80 29 17 6 14 12 18 7 21
Figure 1 | Independent contribution of individual dimensions of overall pain experience to illness severity metrics. Pain
intensity captured 5–85% of the explained variance across metrics. Pain frequency and constancy accounted for most
of the remaining explained variance across metrics. Pain bothersomeness and relief with bowel movements (BM) con-
tributed small amounts to understanding the various metrics. Bars with asterisks indicate statistically significant asso-
ciations. The models explained between 6% and 80% of the overall variance of each outcome; the lowest and highest
explained variance were for generalized anxiety (overall R2 = 6%) and IBS-SSS severity scores (overall R2 = 80%)
respectively. For ease of interpretation, the bars compartmentalize the relative proportion of each metric explained by
the pain dimensions; for reference, the total absolute explained variance is provided above each bar.
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No. therapies 0.04 0.43 0.01 0.06 0.89 0.72 0.006 0.19
IBS-QOL Score <0.001 0.09 0.71 0.004 0.74 0.78 <0.001 0.20
HAD Anxiety Scale Score 0.005 0.58 0.32 0.51 0.62 0.31 0.37 0.05
HAD Depression Scale Score 0.24 0.92 0.15 0.78 0.10 0.49 0.0007 0.16
IBS-SSS severity 0.50 0.25 0.57 0.0001 0.65 0.61 <0.001 0.49
WPAI absenteeism 0.05 0.47 0.17 0.35 0.58 0.85 0.002 0.22
WPAI presenteeism 0.56 0.24 0.84 0.15 0.33 0.84 0.01 0.19
Somatization Score (PHQ-15) 0.0001 0.37 0.29 0.08 0.28 0.18 0.02 0.12
Considerable relief? 0.82 0.03 0.04 0.41 0.77 0.13 0.0007 0.26
Severity of symptoms past week 0.71 0.89 0.93 0.0001 0.53 0.59 <0.001 0.36
Perceived control of pain 0.0005 0.04 0.98 0.78 0.72 0.91 0.27 0.06
Each cell provides the P-value for the beta-coefficient of each pain attribute in the model. Bold values indicate statistical signifi-
cance. The data reveal that pain episode ‘predictability’ (i.e. ability to predict an episode is coming) was the strongest predictor
of IBS-related health across metrics. In contrast to overall intensity of pain (Table 3), intensity of pain episodes was not predictive
across metrics. Similarly, the frequency of acute pain episodes revealed minimal predictive value. The duration of acute pain epi-
sodes revealed intermediate predictive value. Taken together, the pain dimensions explained the largest proportion of variance

































































































Figure 2 | Independent contribution of individual dimensions of acute pain episodes to illness severity metrics. The
data indicated that pain episode predictability captured at least one-third of the explained variance for all metrics
except HAD anxiety. Episode duration and frequency added an additional 25%, on average, across metrics (with
exception of perceived control index, in which frequency was predominant). Pain episode severity and onset speed
captured only small amount of the explained variance across metrics. Bars with asterisks indicate statistically signifi-
cant associations. The absolute proportion of variance explained by each model is listed atop each bar.
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Our study is limited because it is an observational
cohort of patients, not a controlled clinical trial. However,
we believe that there are important benefits of monitoring
IBS patients outside of a clinical trial. Moreover, an obser-
vational cohort is well suited for the purpose of psycho-
metric validation of PROs. In addition, our results cannot
be generalized to all IBS patients. Nonetheless, our cohort
is reflective of other IBS populations as the patients are
primarily middle aged and women, are varied across
demographic characteristics and have distributions across
severity strata that are similar to other clinic patient pop-
ulations.6 Nonetheless, it will be useful to continue this
line of inquiry in other IBS population as PRO develop-
ment activities continue to evolve.
Another limitation is that some illness severity
domains are more apt to cross pain dimensions than
others, and some of this may be driven by circularity.
For example, the IBS-SSS includes a pain intensity scale
and therefore it is not surprising that IBS-SSS scores are
highly related to pain intensity. In contrast, other
domains are purely psychological (e.g. HAD anxiety,
HAD depression, etc.) and have no direct overlap with
pain dimensions and therefore they may be less likely to
cut across dimensions. Other domains fully avoid
circularity, yet still cut across many dimensions simulta-
neously. It is likely that some of the relationships are
partly driven by the structure of the scale, some by the
content of the scale and some by both. Although many
of the relationships emerging from Tables 2 and 3 may
reflect the underlying meaning beyond what we have dis-
cussed here, we are reluctant to over-interpret potentially
the data given the multiple comparisons we have tested
in this exploratory study. However, we do believe that
the findings suggest that any new PRO in IBS should be
multidimensional to cut across concepts, as some (but
not all) of the tested domains accomplish in this study.
In conclusion, we found that abdominal pain in IBS
has several dimensions. Although measuring pain inten-
sity is important to understand the illness experience in
IBS,4 it is necessary but not sufficient to capture symp-
tom burden and impact adequately. Future PROs in IBS
should collect information about various dimensions of
pain, including intensity, frequency, constancy, and pre-
dictability; pain should not be considered unidimen-
sional. In addition, we have developed an online
calculator to help define inclusion criteria for IBS clinical
trials aimed at abdominal pain – this may be an
improvement over the use of arbitrary, non-empirically
based thresholds that are customarily employed. Finally,
clinicians should de-emphasize using the pain as the
‘most bothersome’ symptom to drive treatment decisions
primarily, and should consider focusing on other aspects
of pain to predict illness severity, such as the ability to
predict pain episodes reliably, the frequency of pain and
the presence of pain as a constant feature.
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Figure 3 | Distribution of Patient Ability to Predict Pain
Episodes. Patients were posed the following question:
‘Some people with IBS can predict when a pain episode
is about to come on while others cannot. In thinking
about your IBS pain episodes, how reliably can you pre-
dict, in advance, that an episode is about to happen on
a scale from 0 (IBS episodes are totally unpredictable)
to 10 (IBS episodes are totally predictable)?’ The data
reveal a right skewed distribution with <3% able to
‘totally’ predict their pain episodes. In contrast, the
most common response was that pain episodes were
‘totally unpredictable’.
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